To my way of thinking that's the central question.  Obviously there's some uncertainty as it is, as yet, unproven....we're waiting on confirmation from the BETonMACE trial.  

Personally I think its a multi billion dollar drug in USD if they're able to prove significant RRR for Diabetes patients and MACE....and then multiples more if they're able to prove other indications like CKD.  

That's why the prospect of a secondary, or a PP doesn't concern me.....the current valuation of $225 million CDN I think is a bargain, but that's just my opinion.